secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2026-03-18T23:59:59+00:00
Accession:  0001628280-26-019026
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas reports Phase 1 ARV-102 shows >50% LRRK2 degradation in CSF in Parkinson's patients
--------------------------------------------------------------------------------

- ARV-102 achieved approximately 50% or greater LRRK2 reduction in CSF across all doses (20–80 mg) by day 14, maintained through day 28.
- Treatment was well tolerated; all adverse events were mild, with no serious adverse events, discontinuations, or deaths.
- Endolysosomal and neuroinflammatory biomarkers (e.g., CD68, GPNMB) were reduced in cerebrospinal fluid.
- Mean plasma half-life of ARV-102 was 68 hours; CSF exposure increased dose-dependently indicating brain penetration.
- Company plans Phase 1b trial in progressive supranuclear palsy in Q2 2026, with potential registrational trial in late 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000162828026019026/0001628280-26-019026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000162828026019026/arvn-20260318.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-019026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer